Type of Assessment:
A giant peritoneal mesothelioma extending to the pelvic floor: A case report and review of the literature
Journal of Cancer Research and Therapeutics 2025 April 1 [Link] Mathew Thomas, Harikrishnan Nandakumar, Parth Sampat, Stephen Graziano Abstract Malignant peritoneal mesothelioma (MPM) is a rare malignancy originating from the peritoneal serosa and is the second most common site of mesothelioma after the pleura. Localized disease presents as a focal circumscribed mass, whereas diffuse disease…
Read MoreProlonged Survival in Mesothelioma Patients Without Surgical Resection: A National Cancer Database Analysis
The Annals of Thoracic Surgery 2025 June 28 [Link] Peter L Zhan, Maureen E Canavan, Justin M Bader, Daniel J Boffa, Benjamin J Resio, Gavitt A Woodard Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS 2) trial demonstrated no survival benefit from cytoreductive surgical resection over chemotherapy alone in resectable pleural mesothelioma. Using the…
Read MoreLong term side effects after volumetric modulated arc therapy to the pleura in patients with malignant pleural mesothelioma
Lung Cancer 2025 August [Link] Vishruta Dumane, Juliana Runnels, Raja Flores, Andrea Wolf, Weijia Fu, Madhu Mazumdar, Thomas Marron, Jorge Gomez, Kenneth Rosenzweig Abstract Purpose: Lung-sparing pleurectomy/decortication (P/D) is the primary surgical approach for malignant pleural mesothelioma (MPM), and combining it with other therapies enhances patient outcomes.This report presents the extended follow-up results of MPM…
Read MoreClinical and Pathologic Phenotyping of mesotheliomas developing in carriers of Germline BAP1 Mutations
Journal of Thoracic Oncology 2025 June 27 [Link] Michele Carbone, Michael Minaai, Muaiad Kittaneh, Thomas Krausz, Markku M Miettinen, Qiang Pan Hammarström, Lennart Hammarström, Hassan Abolhassani, Ian Pagano, Ronghui Xu, Flavia Novelli, Giovanni Gaudino, Sandra Pastorino, Kavita Y Sarin, Robert T Ripley, Harvey I Pass, David S Schrump , Haining Yang Abstract Introduction: Mesothelioma is…
Read MoreImmune Composition and Immunotherapy Outcomes of Mesothelioma with BAP1, CDKN2A, MTAP, and NF2 Alterations
Journal of Thoracic Oncology 2025 June 25 [Link] Ibiayi Dagogo-Jack, Owen Mitchell, Elizabeth Codd, Annie Li, Dawn Mitchell, Samantha E Flynn, Nanna Sivamanoharan, Patrick Reeves, Mark Poznansky, Ivan Valiev, Artem Kosmin, Beow Y Yeap, Grace Hambelton, A John Iafrate, Jochen K Lennerz, Yin P Hung, Hedy Kindler Abstract Background: First-line mesothelioma treatment paradigms prioritize histology…
Read MoreHMGB1 as a Key Mediator in Malignant Mesothelioma and a Potential Target for Asbestos-Related Cancer Therapy
Toxics 2025 May 28 [Link] Yi-Fang Zhong, Chan Ding, Chun-Ji Yao, Jia-Chun Wang, Min-Qian Feng, Xiao-Xue Gong, Lin Yu, Hua-Dong Xu, Hai-Ling Xia Abstract Malignant mesothelioma (MM) is a highly aggressive cancer strongly associated with asbestos exposure, and accumulating evidence suggests that high mobility group box 1 (HMGB1) plays a central role in its pathogenesis.…
Read MoreLoss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma
Histopathology 2025 June 25 [Link] Andrea Quaranta, Andrea Marzullo, Francesco Fortarezza, Sonia Maniglio, Concetta Caporusso, Floriana Pentimone, Federica Pezzuto, Domenica Cavone, Teresa Lettini, Mario Magistro, Cecilia Salzillo, Luigi Vimercati, Paolo Graziano, Gabriella Serio, Antonio d’Amati Abstract Aims: Mesothelioma is a malignant neoplasm of the serosal membranes originating from mesothelial cells. Peritoneal mesothelioma is the second…
Read MoreRetreatment With Nivolumab and Ipilimumab in Pleural Mesothelioma Following Disease Progression After a Durable Response: Case Series
JTO Clinical Case Reports 2025 April 21 [Link] Illaa Smesseim, Paul Baas, Jacobus A Burgers Abstract The CheckMate 743 trial established nivolumab and ipilimumab as the standard first-line treatment for unresectable pleural mesothelioma. However, optimal management following disease progression after a durable response to dual immunotherapy remains unclear. We report two cases of patients with…
Read More8C7: A Fully Human Anti-PTGFRN Monoclonal Antibody-Drug Conjugate Inhibiting Tumour Growth of Mesothelioma and Paediatric Medulloblastoma Cell Lines
Journal of Cellular and Molecular Medicine 2025 June [Link] Jorge Marquez, Jianping Dong, Binbin Yue, Jun Hayashi, Chun Dong, Mitsuo Oshimura, Ginette Serrero Abstract Antibody Drug Conjugates (ADCs) are attractive for developing cancer-targeted therapies, particularly for cancers with unmet needs. Identification of a druggable internalising cell-surface target enables the development of internalising monoclonal antibodies to…
Read MorePBK Expression Promotes the Aggressive Phenotypes of Mesothelioma
Cancer Science 2025 June 24 [Link] Kazumi Hori, Ichidai Tanaka, Tatsuhiro Sato, Mika Sato, Yuta Kodama, Hideyuki Itoigawa, Yuichi Abe, Taketo Kato, Ayumu Taguchi, Mitsuo Sato, Yoshitaka Sekido, Toyofumi Fengshi Chen-Yoshikawa, Makoto Ishii Abstract Mesothelioma is one of the most aggressive neoplasms worldwide that has a particularly poor prognosis. We have previously discovered that oxytocin…
Read More
Skip to content